JULIE HEEB: Open Payments
NPI 1093101958 · POPLAR BLUFF, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,214 in 56 payments from 10 companies in 2025. Trend: 2023 $399 · 2024 $738 · 2025 $1,214
Food & beverage: $1,214
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $338 |
| Alkermes, Inc. | 11 | $204 |
| Lundbeck LLC | 7 | $142 |
| E.R. Squibb & Sons, L.L.C. | 8 | $137 |
| Otsuka America Pharmaceutical, Inc. | 5 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $77 |
| Neurocrine BioSciences, Inc. | 3 | $73 |
| Janssen Pharmaceuticals, Inc | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $53 |
| ABBVIE INC. | 2 | $36 |
Products named: UZEDY, ARISTADA, ABILIFY ASIMTUFII, COBENFY, REXULTI, FANAPT, INGREZZA, INVEGA SUSTENNA.
Industry payments across MO — which companies pay providers there.
